Analyst Reco. BioLineRx Ltd.

Equities

BLRX

IL0011015182

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 13:49:49 12/05/2024 BST			5-day change	1st Jan Change
16.2 ^ILa	-0.61%		-2.99%	-57.59%

04-17	BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	CI
04-10	BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Raises BioLineRx's Price Target to $21 From $19, Maintains Buy Rating	15/09/23	MT
BIOLINERX : HC Wainwright Adjusts BioLineRx' Price Target to $19 from $22, Keeps Buy Rating	23/02/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer